Neutropenia  >>  Halaven (eribulin mesylate)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
NCT00326950: Phase I Clinical Study of E7389

Completed
1
15
Japan
E7389
Eisai Co., Ltd.
Cancer
01/08
02/08
NCT01432886: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Checkmark In combination withEribulin mesylate for adv/recurrent HER2+ve BC
Sep 2014 - Sep 2014: In combination withEribulin mesylate for adv/recurrent HER2+ve BC
Completed
1
12
Japan
E7389
Eisai Co., Ltd.
Breast Cancer
08/13
12/13
BOLD 113, NCT02171260 / 2016-001894-34: This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

Completed
1
23
US
Eribulin Mesylate, E7389
Eisai Inc., Children's Oncology Group
Pediatrics, Solid Tumors
01/16
01/16

Download Options